Avid Bioservices (CDMO) Misses Q2 EPS by 9c, adjusts guidance

Avid Bioservices (NASDAQ: CDMO) reported Q2 EPS of ($0.15), $0.09 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $25.4 million versus the consensus estimate of $33.22 million.

GUIDANCE:

Avid Bioservices sees FY2024 revenue of $137-147 million, versus the consensus of $154.1 million.

For earnings history and earnings-related data on Avid Bioservices (CDMO) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Lennar Corp. (LEN) Misses Q3 EPS by 10c
• Element Solutions (ESI) PT Lowered to $47 at UBS, Buy Rating Maintained